{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:00:57Z","timestamp":1790283657470,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical Co., Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical Co., Ltd, Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ejca.2018.09.024","type":"journal-article","created":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T21:29:57Z","timestamp":1541107797000},"page":"41-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"special_numbering":"C","title":["Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to\u00a0trastuzumab (KSCC1604)"],"prefix":"10.1016","volume":"105","author":[{"given":"Hiroshi","family":"Saeki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Kashiwada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Arigami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitaka","family":"Makiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Iwatsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiya","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironaga","family":"Satake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Maehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2018.09.024_bib1","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/annonc\/mdn169","article-title":"HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target","volume":"19","author":"Gravalos","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.09.024_bib2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/annonc\/mdi064","article-title":"Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab","volume":"16","author":"Tanner","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.09.024_bib3","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","article-title":"Assessment of a HER2 scoring system for gastric cancer: results from a validation study","volume":"52","author":"Hofmann","year":"2008","journal-title":"Histopathology"},{"key":"10.1016\/j.ejca.2018.09.024_bib4","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/PAT.0b013e3283513e8b","article-title":"Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas","volume":"44","author":"Cho","year":"2012","journal-title":"Pathology"},{"key":"10.1016\/j.ejca.2018.09.024_bib5","first-page":"4207","article-title":"Significance of accurate human epidermal growth factor receptor-2 (HER2) evaluation as a new biomarker in gastric cancer","volume":"34","author":"Kimura","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2018.09.024_bib6","first-page":"2441","article-title":"Correlation of HER2 expression with clinicopathological characteristics and prognosis in resectable gastric cancer","volume":"35","author":"Otsu","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2018.09.024_bib7","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2018.09.024_bib8","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2013.53.6136","article-title":"Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study","volume":"32","author":"Satoh","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.09.024_bib9","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S1470-2045(17)30111-0","article-title":"Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2\/3 study","volume":"18","author":"Thuss-Patience","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.09.024_bib10","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1093\/annonc\/mdt364","article-title":"Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients","volume":"24","author":"Guarneri","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.09.024_bib11","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.2010.33.8889","article-title":"Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors","volume":"30","author":"Niikura","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.09.024_bib12","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/annonc\/mdv611","article-title":"Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry","volume":"27","author":"Niikura","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.09.024_bib13","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10120-015-0502-3","article-title":"Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer","volume":"19","author":"Tominaga","year":"2016","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ejca.2018.09.024_bib14","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1172\/JCI75200","article-title":"Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma","volume":"124","author":"Kim","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2018.09.024_bib15","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.3748\/wjg.v22.i19.4619","article-title":"HER2 testing in gastric cancer: an update","volume":"22","author":"Abrahao-Machado","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejca.2018.09.024_bib16","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00428-010-0952-2","article-title":"HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing","volume":"457","author":"Ruschoff","year":"2010","journal-title":"Virchows Arch"},{"key":"10.1016\/j.ejca.2018.09.024_bib17","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.3_suppl.63","article-title":"Loss of human epidermal growth factor receptor 2 (HER2) expression in HER2-overexpressing esophagogastric (EG) tumors treated with trastuzumab","volume":"33","author":"Janjigian","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.09.024_bib18","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1002\/ijc.30408","article-title":"HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: implication for further clinical research","volume":"139","author":"Pietrantonio","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2018.09.024_bib19","doi-asserted-by":"crossref","first-page":"61837","DOI":"10.18632\/oncotarget.18700","article-title":"Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer","volume":"8","author":"Soo Park","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2018.09.024_bib20","doi-asserted-by":"crossref","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ejca.2018.09.024_bib21","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/modpathol.2012.36","article-title":"Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance","volume":"25","author":"Seol","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ejca.2018.09.024_bib22","doi-asserted-by":"crossref","first-page":"9262","DOI":"10.18632\/oncotarget.24265","article-title":"Prognostic implications of HER2 heterogeneity in gastric cancer","volume":"9","author":"Motoshima","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2018.09.024_bib23","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology","volume":"35","author":"Bartley","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.09.024_bib24","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s10120-013-0329-8","article-title":"Importance of formalin fixing conditions for HER2 testing in gastric cancer: immunohistochemical staining and fluorescence in situ hybridization","volume":"17","author":"Yamashita-Kashima","year":"2014","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ejca.2018.09.024_bib25","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1158\/2159-8290.CD-15-0748","article-title":"Molecular heterogeneity and receptor coamplification drive resistance to targeted therapy in MET-amplified esophagogastric cancer","volume":"5","author":"Kwak","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2018.09.024_bib26","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/ijc.29159","article-title":"HER2-positive gastric cancer with concomitant MET and\/or EFRA overexpression: a distinct subset of patients for dual inhibition therapy","volume":"136","author":"Ha","year":"2015","journal-title":"Int J Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918313947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918313947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T08:52:44Z","timestamp":1605343964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918313947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":26,"alternative-id":["S0959804918313947"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.09.024","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to\u00a0trastuzumab (KSCC1604)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.09.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}